UFP Technologies — Q3 2026 Earnings Summary

Financial Performance:

• Net sales for the quarter ended September 30, 2026, were $172.4 million, an 11.6% increase from $154.6 million in the same period of 2025.
• Net sales for the nine-month period ended September 30, 2026, were $500.6 million, a 10.3% increase from $453.9 million in the same period of 2025.
• Organic sales growth was 11.1% for the quarter and 7.9% for the nine-month period.
• Net income for the quarter was $20.6 million, a 25.8% increase from $16.4 million in 2025; for the nine-month period, net income was $59.0 million, a 16.2% increase from $50.7 million.
• GAAP diluted EPS for the quarter was $2.64 (vs. $2.11 in 2025); for the nine-month period, it was $7.56 (vs. $6.52).
• Adjusted diluted EPS for the quarter was $2.88 (vs. $2.39 in 2025); for the nine-month period, it was $8.28 (vs. $7.34).
• Gross margin increased to 29.4% for the quarter (from 27.7% in 2025) and 29.2% for the nine-month period (from 28.3%).
• Operating income increased 18.1% to $27.6 million for the quarter (from $23.4 million) and 11.6% to $79.1 million for the nine-month period (from $70.8 million).
• Adjusted operating income increased 14.5% to $30.1 million for the quarter (from $26.3 million) and 9.0% to $86.6 million for the nine-month period (from $79.4 million).
• Adjusted EBITDA increased 15.3% to $35.4 million for the quarter (from $30.7 million) and 10.7% to $102.8 million for the nine-month period (from $92.8 million).
• SG&A expenses increased 21.4% to $23.2 million for the quarter (from $19.1 million) and 18.5% to $66.9 million for the nine-month period (from $56.5 million).
• Adjusted SG&A as a percentage of sales was 12.0% for the quarter and 11.9% for the nine-month period.
• Cash and cash equivalents were $20.6 million as of September 30, 2026, compared to $20.3 million as of December 31, 2025.
• Total debt (current and long-term) was $96.0 million as of September 30, 2026, compared to $135.5 million as of December 31, 2025.

Guidance and Future Outlook:

• Management expressed optimism regarding the strength and positioning of UFP for 2027.
• The company has invested in additional capacity at DAS Medical to support double-digit growth.
• Management continues to identify attractive acquisition opportunities and is making progress on several.
• The company is working to expand its credit facility to increase capacity for investing in high-quality businesses.
• Management anticipates realizing benefits from new programs and facility expansions in the Dominican Republic, though program transfers and margin improvements in legacy operations remain behind plan.

Business Segments and Product Lines:

• MedTech sales grew 12.5% in the third quarter and 11.7% year-to-date.
• Top five MedTech customers collectively grew 11.7% year-to-date.
• The company is scaling new programs in the Dominican Republic.
• The 2025 investment in TPI has exceeded expectations, providing an initial position in injection molding.
• Significant year-over-year progress was noted at AJR in both the U.S. and the Dominican Republic.

Market and Competitive Landscape:

• The company serves a wide range of medical product segments including robotic assisted surgery, patient beds, infection control, cardiovascular, orthopedics, spine, and wound care.
• Management highlighted the balance, diversity, and durability of its portfolio of operating businesses.

Risks and Challenges:

• Scheduled program transfers to the Dominican Republic and margin improvements in legacy operations are currently behind plan.
• Risks include potential delays in production, supply chain disruptions, labor force issues, and risks associated with new program launches.
• Risks related to customer concentration, specifically the two largest customers, include the potential for reduced orders, cancellation, or self-manufacturing.
• Risks include geopolitical uncertainties, trade barriers, tariffs, and cybersecurity threats.
• Risks associated with indebtedness and compliance with financing covenants, including the success of efforts to expand the credit facility.

Management Commentary and Tone:

• Mitch Rock, President and CEO, stated that results reflect "continued solid execution" and progress toward the long-term growth strategy.
• Management noted "meaningful improvements" across businesses, including scaling new programs and margin improvements.
• The tone regarding 2027 is described as "optimistic" due to the company's strength and positioning.
• Management emphasized the ability to onboard larger businesses and create long-term value with a strong balance sheet and expanded team.

Other Key Points:

• The company reported a gain on disposal of property, plant, and equipment of $9,000 for the quarter and $41,000 for the nine-month period.
• Acquisition costs were $12,000 for the quarter and $84,000 for the nine-month period.
• A change in fair value of contingent consideration resulted in a $263,000 expense in the prior year quarter but was $0 in the current quarter.
• The company has scheduled a conference call for November 4, 2026, at 8:30 AM Eastern time.
• The company is actively investing in broadening capabilities, specifically citing the TPI acquisition for injection molding and progress at AJR.